A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Kolyada, Alexey ^a   Lee, Chang Jin ^a   De Biasio, Alfredo ^a   Beglova, Natalia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E RECEPTOR 2; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN; LIPOPROTEIN RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; DISULFIDE;

AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; LIGAND BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; ANIMAL; AUTOIMMUNITY; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; FEMALE; HUMAN; IMMUNOLOGY; METHODOLOGY; MOUSE; PREGNANCY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; RECURRENT ABORTION; X RAY CRYSTALLOGRAPHY;

ABORTION, HABITUAL; ANIMALS; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DISULFIDES; FEMALE; HUMANS; MICE; PREGNANCY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 78650722311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015345     Document Type: Article

References (61)

1. Atsumi T, Amengual O, Yasuda S, Matsuura E, Koike T (2005) Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies. Autoimmunity 38: 377-381.
2. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, et al. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 1544-1547.
3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87: 4120-4124.
4. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306.
5. George D, Erkan D (2009) Antiphospholipid syndrome. Prog Cardiovasc Dis 52: 115-125.
6. Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295: 1050-1057.
7. McNall-Knapp RY (2008) Thrombolysis in antiphospholipid syndrome: current hematologic perspectives. Curr Rheumatol Rep 10: 62-66.
8. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, et al. (1999) Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. Embo J 18: 5166-5174.
9. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, et al. (1999) Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J 18: 6228-6239.
10. Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, et al. (2002) Solution structure of human and bovine beta(2)-glycoprotein I revealed by smallangle X-ray scattering. J Mol Biol 321: 85-97.
11. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, et al. (2010) {beta}2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood 116: 1336-1343.
12. Lin F, Murphy R, White B, Kelly J, Feighery C, et al. (2006) Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus 15: 87-93.
13. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG (2004) beta2- glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104: 3598-3602.
14. Guerin J, Casey E, Feighery C, Jackson J (1999) Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity 31: 109-116.
15. de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, et al. (2009) The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost.
16. Ioannou Y, Romay-Penabad Z, Pericleous C, Giles I, Papalardo E, et al. (2009) In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 7: 833-842.
17. Cugno M, Borghi MO, Lonati LM, Ghiadoni L, Gerosa M, et al. (2010) Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun 34: 105-110.
18. Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28: 129-133.
19. Pierangeli SS, Vega-Ostertag M, Harris EN (2004) Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 114: 467-476.
20. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, et al. (2003) Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 29. J Biol Chem 278: 33831-33838.
21. Pennings MT, Derksen RH, van Lummel M, Adelmeijer J, VanHoorelbeke K, et al. (2007) Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 29. J Thromb Haemost 5: 369-377.
22. Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, et al. (2006) Anti-beta2- glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 54: 2558-2567.
23. Cockrell E, Espinola RG, McCrae KR (2008) Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus 17: 943-951.
24. Raschi E, Borghi MO, Grossi C, Broggini V, Pierangeli S, et al. (2008) Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus 17: 937-942.
25. Urbanus RT, Pennings MT, Derksen RH, de Groot PG (2008) Platelet activation by dimeric beta(2)-glycoprotein I requires signaling via both glycoprotein Ibalpha and Apolipoprotein E Receptor 29. J Thromb Haemost.
26. Pierangeli SS, Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, et al. (2007) Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 66: 1327-1333.
27. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, Papalardo E, Vargas G, et al. (2009) Annexin A2 is involved in antiphospholipid antibodymediated pathogenic effects in vitro and in vivo. Blood 114: 3074-3083.
28. Urbanus RT, Derksen RH, de Groot PG (2008) Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev 22: 93-105.
29. Rand JH, Wu XX, Quinn AS, Taatjes DJ (2010) The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19: 460-469.
30. Hunt J, Krilis S (1994) The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 152: 653-659.
31. Mehdi H, Naqvi A, Kamboh MI (2000) A hydrophobic sequence at position 313-316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (beta2- glycoprotein I) is crucial for cardiolipin binding. Eur J Biochem 267: 1770-1776.
32. Sanghera DK, Wagenknecht DR, McIntyre JA, Kamboh MI (1997) Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding. Hum Mol Genet 6: 311-316.
33. Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA (1996) Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 157: 3744-3751.
34. van Lummel M, Pennings MT, Derksen RH, Urbanus RT, Lutters BC, et al. (2005) The binding site in {beta}2-glycoprotein I for ApoER29 on platelets is located in domain V. J Biol Chem 280: 36729-36736.
35. Bancsi LF, van der Linden IK, Bertina RM (1992) Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 67: 649-653.
36. Takeuchi R, Atsumi T, Ieko M, Takeya H, Yasuda S, et al. (2000) Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 96: 1594-1595.
37. Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, et al. (2000) beta(2)- glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152: 337-346.
38. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA (2009) How we diagnose the antiphospholipid syndrome. Blood 113: 985-994.
39. Roubey RA, Eisenberg RA, Harper MF, Winfield JB (1995) "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 154: 954-960.
40. Sheng Y, Kandiah DA, Krilis SA (1998) Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol 161: 2038-2043.
41. Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, et al. (1996) The anti-beta2- glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 157: 5732-5738.
42. Herz J, Bock HH (2002) Lipoprotein receptors in the nervous system. Annu Rev Biochem 71: 405-434.
43. Jeon H, Blacklow SC (2005) Structure and physiologic function of the lowdensity lipoprotein receptor. Annu Rev Biochem 74: 535-562.
44. Pennings MT, van Lummel M, Derksen RH, Urbanus RT, Romijn RA, et al. (2006) Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost 4: 1680-1690.
45. Pennings MT, Derksen RH, Urbanus RT, Tekelenburg WL, Hemrika W, et al. (2007) Platelets express three different splice variants of ApoER2 that are all involved in signaling. Journal Thromb Haemost 5: 1538-1544.
46. Lee CJ, De Biasio A, Beglova N (2010) Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. Structure 18: 366-376.
47. Abdul-Aziz D, Fisher C, Beglova N, Blacklow SC (2005) Folding and binding integrity of variants of a prototype ligand-binding module from the LDL receptor possessing multiple alanine substitutions. Biochemistry 44: 5075-5085.
48. Beglov D, Lee CJ, De Biasio A, Kozakov D, Brenke R, et al. (2009) Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors. Proteins 77: 940-949.
49. Fisher C, Beglova N, Blacklow SC (2006) Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol Cell 22: 277-283.
50. Blacklow SC (2007) Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr Opin Struct Biol 17: 419-426.
51. van Os GM, Urbanus RT, Agar C, Meijers JC, de Groot PG (2010) Antiphospholipid syndrome. Current insights into laboratory diagnosis and pathophysiology. Hamostaseologie 30: 139-143.
52. Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, et al. (1996) Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2- glycoprotein I complexes to lipid membranes. Biochemistry 35: 13833-13842.
53. Giles IP, Isenberg DA, Latchman DS, Rahman A (2003) How do antiphospholipid antibodies bind beta2-glycoprotein I? Arthritis Rheum 48: 2111-2121.
54. North CL, Blacklow SC (2000) Solution structure of the sixth LDL-A module of the LDL receptor. Biochemistry 39: 2564-2571.
55. Luft JR, Collins RJ, Fehrman NA, Lauricella AM, Veatch CK, et al. (2003) A deliberate approach to screening for initial crystallization conditions of biological macromolecules. J Struct Biol 142: 170-179.
56. Leslie AG (2006) The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 62: 48-57.
57. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
58. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
59. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
60. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
61. DeLano WL (2002) ThePyMOL Molecular Graphics System. Palo Alto, CA, USA: DeLano Scientific.